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Immunodeficiency and chronic myelogenous leukemia-like syndrome in mice with a targeted mutation of the ICSBP gene. Hematopoietic stem cell fate has been largely associated with a regulatory environment commonly referred to as niche. 1 It remains unclear whether this microenvironment in the bone marrow is located in the endosteal region, the perivasculature or both. 2 Nevertheless, direct cell-cell contact, soluble factors and extracellular matrix components have been implicated in the support of hematopoietic stem cells. Interestingly, most of these regulatory signals have also been associated with Letters to the Editor regulating the fate of leukemic cells. Among these, the chemokine CXCL12, also called stromal derived factor 1a (SDF-1a), expressed by marrow stromal cells and osteoblasts is essential for both homing and retention of hematopoietic stem cell in the bone marrow. 3 Most importantly, Tavor and colleagues demonstrated using a transplant model in immunodeficient NOD/SCID/B2m null mice that the motility of human acute myeloid leukemia (AML) cells relies on the SDF-1/CXCR4 axis. 4 Preclinical experiments suggest that the interaction of leukemic blasts with bone marrow components may protect cells against chemotherapy. [5] [6] [7] Using a murine model of minimal residual disease, Matsunaga et al. showed that the combination of the cytotoxic drug cytosine arabinoside with a blocking antibody against integrin a 4 (VLA-4) increases significantly the survival rate of mice as compared with those treated with arabinoside only. 8 More recently, Jin et al. reported that targeting the hyaluronic acid receptor CD44 eradicates leukemic stem cells in a murine serial transplantation model. 9 Both reports suggest that the disruption of the interaction of leukemic cells and their bone marrow microenvironment is of primary importance for the effects observed in these animal studies. Nevertheless, to our knowledge no clinical data in humans supports this hypothesis. Here we report our first Letters to the Editor clinical experience with an AML patient treated with the CXCR4 antagonist AMD3100 within a compassionate use program in combination with standard chemotherapy.
A 52-year-old patient was diagnosed with relapse of AML FAB M0 17 months after having undergone allogeneic stem cell transplantation from a matched sibling donor. The indication for transplantation had been the primary refractory disease after the first induction therapy. The post-transplant course had been complicated by sinusoidal obstruction syndrome of the liver and pneumonia. By the time of relapse, the patient presented with a white blood cell count of 7.1 Â 10 9 /l with 70% of myeloblasts in the periphery. Bone marrow aspiration revealed 80% of CD34 þ /CD133 þ myeloblasts (3 Â 10 7 blasts/ml). On account of the undifferentiated phenotype and the history of refractory disease at initial diagnosis, we decided to combine CXCR4/SDF-1 antagonism and reinduction chemotherapy. AMD3100 Octahydrochloride (Sigma Aldrich, St Louis, USA) was prepared and provided by the hospital pharmacy within a compassionate use program. After obtaining informed consent, 240 mg/kg of the compound were administered subcutaneously 24 and 2 h before the start of reinduction therapy. The chemotherapy regimen contained arabinoside 1000 mg/m 2 intravenously over 4 h on 4 consecutive days, fludarabine 30 mg/m 2 intravenously for 30 min before each arabinoside administration and idarubicin 8 mg/m 2 as bolus injection on days one and three. Bone marrow aspirates were taken before each application of AMD3100 and 28 days after the end of chemotherapy. The consecutive chemotherapy induced aplasia in the peripheral blood with no circulating blasts. As the bone marrow aspirate on day 28 revealed persistent leukemia, a second allogeneic transplantation was scheduled with peripheral blood stem cells from a HLA-matched sibling donor after reduced-intensity conditioning. Trilineage hematologic engraftment and complete remission could be documented 1 month after transplantation. Unfortunately, the patient died 5 months after transplantation from steroid refractory graft-versus-host disease. No signs of relapse could be documented during this follow-up period.
As seen in Figure 1 , in vivo blockade of the SDF-1/CXCR4 interaction induced a reduction of CD34 þ blasts in the bone marrow (84 vs 47%). Although the percentage of CD34 þ blasts in the peripheral blood remained rather constant, the induced increase of the total white blood cell count up to 23.7 Â 10 9 /l suggests a net mobilization of leukemic cells into peripheral circulation. To evaluate whether CXCR4 antagonism changed the expression of adhesion molecules and CXCR4 on blasts in the bone marrow, we performed additional fluorescence activated cell sorting before and after treatment (Figure 2 ). We observed no significant change in the expression of integrins a 5 (CD49e) and b 1 (CD29). The reduction of integrin a 4 (CD49d) and CD44 expression was more pronounced. However, the strongest decrease was observed in the expression of CXCR4 itself (CD184), arguing for the specificity of AMD3100. This observation is in line with our own previously published data. 10 It remains to be speculated how AMD3100 induces these phenotypic changes. We hypothesized that leukemic cells expressing high levels of CD44, integrin a 4 and CXCR4 exit the bone marrow upon CXCR4/SDF-1 blockade. It has also been proposed that binding of AMD3100 to CXCR4 blocks the recognition of CXCR4 by the antibody (clone 12G5) used in this assay. 11 This case report suggests that the administration of AMD3100 has a major impact on the retention of AML blasts within the marrow microenvironment. As previously shown in vitro and in preclinical animal models, the blockade of CXCR4 induces a mobilization of leukemia cells from the marrow into the peripheral blood. Earlier studies suggest that CXCR4 antagonists can have additional effects on leukemia cell migration, homing and potentially on the induction of apoptosis. 4, 12 The effects of CXCR4 blockade may differ among different subtypes of acute leukemia. Juarez and co-workers showed that AMD3100 can enhance the chemo-responsiveness of acute lymphoblastic leukemia cultured on marrow stromal cells. 13 Two groups have presented preliminary evidence with animal models and in primary human samples suggesting that cytarabine and CXCR4 blockade act synergistically in acute promyelocytic leukemia (AML M3). 12, 14 According to these authors, AMD3100 is able to overcome the chemoresistance mediated by the adhesion of leukemia blasts to marrow stromal cells. In addition, these studies suggest that the timing and sequence of chemokinereceptor blockade and chemotherapy are crucial to obtain the desired synergistic effects. Recently, several groups including our own published data showing that the SDF-1/CXCR4 axis may be of special relevance in AML blasts carrying a FLT3-mutation. [15] [16] [17] Whether these findings are of practical relevance and predict response to therapy has to be tested in clinical trials.
To our knowledge, this is one of the first reports on the combination of in vivo SDF-1/CXCR4 blockade and chemotherapy in a patient with AML. No definitive conclusions on the synergy between AMD3100 and chemotherapy can be drawn from this limited experience, but still our data support the notion that this strategy should be tested in clinical studies in patients with refractory or relapsed AML. Formal dose-finding studies and adaptive designs to optimize the application schedule are needed. Caution is warranted in patients with high white blood cell counts in whom SDF-1/CXCR4 blockade may lead to leukostatic vascular or pulmonary complications. With the advent of new targeted therapies developed for acute leukemias, strategies aiming to interfere with the leukemic niche may help to further improve the outcome of selected patients.
Absolute quantitative detection of ABL tyrosine kinase domain point mutations in chronic myeloid leukemia using a novel nanofluidic platform and mutation-specific PCR ABL is the main target of several tyrosine kinase inhibitors used in the treatment of chronic myeloid leukemia (CML) patients. ABL tyrosine kinase domain (TKD) point mutations are the main mechanism of acquired tyrosine kinase inhibitor resistance. [1] [2] [3] Although approximately 90 ABL TKD point mutations at 57 residues have been described, substitutions at seven amino-acid residues account for a large proportion of point mutations detected. The T315I and the ATP-binding loop (p-loop) mutations have been associated with poor outcomes on imatinib mesylate (IM) therapy in several studies. 2, 3 Furthermore, the 'gatekeeper' mutation, T315I, is resistant to currently available ABL tyrosine kinase inhibitors.
Direct nucleotide sequencing is the primary method of ABL TKD point mutation detection used in clinical practice. This technique has a sensitivity of 20-25% (that is, to be detected the mutant clone must comprise at least 20% of the sample tested). Sensitivity can be improved slightly by pyrosequencing or denaturing high-performance liquid chromatography methods. Because of this limited sensitivity, ABL TKD mutations are typically detected at relapse, rather than early in the course of the emergence of a mutated ABL clone. 2 We have devised a mutation-specific PCR assay using a novel nanofluidic platform to identify and quantify T315I ABL in 34 CML patient samples from 28 patients. 4 The Fluidigm BioMark Real-Time PCR System and a nanofluidic chip, the BioMark digital array (Fluidigm, South San Francisco, CA, USA) were used in conjunction with mutation-specific PCR to detect the T315I mutation. The digital array uses nanoscale channels, valves and pumps to partition samples into 12 panels, each panel containing either 765 or 1104 chambers (depending on the platform design). There is improvement in the detection of rare mutations as a consequence of sample partitioning before PCR. For example, if a mixture containing 1 molecule of T315I ABL in 100 000 molecules of unmutated ABL is partitioned into 1000 independent chambers, the chamber containing the single mutant molecule now only contains B100 molecules of unmutated ABL. This 1000-fold increase in relative concentration theoretically allows for a 1000-fold improvement in the detection sensitivity of PCR reactions, thereby facilitating rare copy detection in limited patient samples. Figure 1 Mutation detection sensitivity. T315I mutated ABL plasmids were diluted serially into a background of 100 000 unmutated ABL plasmids. The number of mutations was calculated using a Poisson distribution. The plot shows the actual number of T315I molecules loaded (Y axis) versus the number of T315I molecules detected (X axis). Single molecules of T315I can be detected in a background of unmutated ABL. From 3 to 30 000 T315I cDNA molecules were detected in a highly reproducible manner in replicate experiments.
